Epetraborole is under clinical development by AN2 Therapeutics and currently in Phase III for Mycobacterium avium Infections. According to GlobalData, Phase III drugs for Mycobacterium avium Infections have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Epetraborole’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Epetraborole overview

Epetraborole is under development for the treatment of mycobacterium avium complex, or MAC, the most common type of NTM, mycobacterium abscessus and melioidosis. The drug candidate is administered as intravenous infusion and through oral route. It is a systemic antibiotic. It acts by targeting the bacterial enzyme leucyl tRNA synthetase. Leucyl tRNA synthetase is an alpha monomer. It is developed based on boron chemistry technology platform.

It was also under development for gram-negative bacterial infections including Enterobacteriaceae infections, Escherichia coli infections, Klebsiella pneumoniae infections and complicated urinary tract infections including acute pyelonephritis and intra-abdominal infections.

AN2 Therapeutics overview

AN2 Therapeutics is a biopharmaceutical company. The company is focused on the research, development, and commercialization of medicines targeting infectious diseases. An2 Therapeutics is headquartered in the US.

For a complete picture of Epetraborole’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.